The study design has been previously disseminated. However, under the study design, the authors fail to mention that they repeated the survey with a small group of physicians, more recently, to assess if there were any changes due to the old nature of the data being used in this paper. This alteration in study design should have been mentioned earlier as it begs the question whether this is a cross-sectional survey or if some of it has a longitudinal aspect as it is clear that some of the participants in the more recent survey also participated in the original survey. There is no discussion around this nor any attempts made to discuss how those being surveyed for a second time, may have influenced or biased the results the second time. There is also no ethical approval mentioned to repeat this survey nor is there justification given for using only one country.
In any research, the reliability and validity of the tools determines the rigour of the findings. In this cross-sectional survey, the reliability and validity of the questionnaire utilised is not reported. The lack of validity of the questionnaire is acknowledged within the limitations but this should have been addressed in the methodology of the study.
It is good to see that missing data was acknowledged and this was addressed through statistical analysis.
Results
There is a sweeping statement made about the number of patients seen per week. It is stated that most German physicians saw 300 patients per week and others saw approximately 100 patients per week. From Table 1 , German physicians saw 275 (SD 150) and Swedish physicians 50 (SD22) per week. When such accurate figures are presented in the Table, it seems unusual for these to be rounded up for the text in the way in which they have been. Some of the percentages cited in the rest of this first paragraph of results appear to contradict what is presented in Table 1 . No comment is made on the low reporting of physician's reporting HBA1c according to guidelines. Table 3 could be presented more clearly. The results of the sensitivity analysis should be given and not just cited without any evidence. Tables 3 and 4 present data on patient education but no comment is made about this in the results section.
Discussion
Summary of findings It is stated that physicians initiate insulin when HbA1c levels are above 53 mmol/mol for both vignettes however this is not obvious from the data presented.
There is no discussion on patient education. All data collected for a study should be discussed and analysed and this appears to be an omission. The old data set is acknowledged although it was collected as party of a larger study. The authors attempt to address this by altering the design of the study that is inappropriate. Under 'Comparison with existing literature' the authors state that the data suggests that the HbA1c is often above 60 mmol/mol before insulin is initiated. Again, this is not obvious from the results.
The paper would benefit from the more consistent use of terminology e.g. Vignette or case study; Dutch or people from the Netherlands. Reference 32 is incomplete. Appendices 1 and 2 are irrelevant. Appendix 1: The complete data and percentages needs to be clarified. As it stands, it does not make sense and the mathematics does not add up. It is almost a duplication of Table 1 . Appendix 2 refers to the 'add on' study. A. Sweden used to have a different HbA1c reference method (Mono-S) compared to other countries. We have now described this in the Methods section, Statistical analyses paragraph, on page 8-9 as follows: "We used the formula "(10.93*HbA1c in %) -23.50" to convert NGSP HbA1c (%) to IFCC HbA1c (mmol/mol); for Sweden we used "(10.11*HbA1c in %) -8.94" to convert the nationally used Mono-S HbA1c (%) to IFCC HbA1c (mmol/mol)." Q. Please clarify these statements 1. Physicians were recruited from both primary and specialist care.
VERSION 1 -AUTHOR RESPONSE
2. Physicians active in both primary and secondary care setting were considered specialists and categorised as such.
So the first statement suggest that "physicians" refers to all participating clinicians, while the second statement suggests that "physicians" just refers to specialist practitioners. Perhaps you should use the terms GP/Specialist and primary/secondary care setting and use clinicians to refer to all participants?
A. We agree with the reviewer that the second statement is indeed confusing. We therefore omitted this statement (Methods section, Data collection paragraph, page 7). It only applied to one physician, and moreover it was not consistent with the previous GUIDANCE publication.
Q. You say "Germany, physicians saw over 300 patients per week" but in the Table the mean is 275? A. Thank you for pointing this out. We accidentally stated the mean in the text, and the median in the table. We now also report the median in the text as follows: "In Germany, physicians saw a median number of 275 patients per week" (Results section, page 10).
Q. This statement is a bit confusing "When comparing the difference in HbA1c levels at which insulin would be initiated between vignette 1 and 2, physicians from Belgium, France and Italy would initiate insulin at a slightly lower HbA1c level in vignette 2" When "comparing the difference" shouldnt you say it is larger or smaller? If you are comparing whether the level chosen in Vignette 1 is higher or lower than the level chosen in vignette 2, then you could make the statement you have made A. We rewrote the text to make the direction more clear (Results section, page 11, second paragraph).
Q. In Table 1 does "Physician reported HbA1c according to guidelines (mmol/mol)" refer to the "The mean general HbA1c target chosen"? Perhaps say that or clarify what you mean.
A. In the methods section we described what this refers to, namely: "the target HbA1c these guidelines recommended according to the physician". We changed the text in tables 1, 3 and 4 to: "Target HbA1c in guideline according to physician" to make it more clear.
Q. The next row down is probably best labbeled as "pre 2009" as using "<" is confusing A. Thank you for the suggestion, the '<2009' label might indeed be confusing, as proven as it was interpreted. We chose to use "valid in 2009" instead, because this reflects our intended definition better.
Q. In Table 3 and 4 can you label the 2 sets of multi variable regression analyses to clarify how they are different A. In the methods section we described these analyses as follows: "First, all variables except for country were investigated in a univariable linear regression (model 1), secondly in a multivariable linear regression (model 2), and finally country was added to the multivariable model (model 3). Country was added last since we wanted the emphasise its role.". We now have repeated this information in the column names of table 3 and 4, to make the differences between the first and the second multivariable analysis more clear.
Reviewer: 2
Reviewer Name: Nicolle Müller Institution and Country: University Hospital Jena Department of Internal Medicine III Jena Germany Please state any competing interests or state 'None declared': None declared Q. This is a very interesting and clear written manuscript about the HbA1c level at which physicians start Insulin therapy in different cases and in different countries. The introduction is well written and makes the case for the study. The aims are clearly stated and the outcome measures match the aims. The methods are well described. The data have been appropriately analysed and are well presented. The discussion is well written.
A. We thank the reviewer for her comment. This study presents data from across eight European countries that is commendable and unique. There is a succinct, referenced introduction that leads into the aims of the study.
Q. The study design has been previously disseminated. However, under the study design, the authors fail to mention that they repeated the survey with a small group of physicians, more recently, to assess if there were any changes due to the old nature of the data being used in this paper. This alteration in study design should have been mentioned earlier as it begs the question whether this is a cross-sectional survey or if some of it has a longitudinal aspect as it is clear that some of the participants in the more recent survey also participated in the original survey. There is no discussion around this nor any attempts made to discuss how those being surveyed for a second time, may have influenced or biased the results the second time.
A. We thank the reviewer for these remarks. We added an extra paragraph to the methods section entitled "sub-study" (Methods section, page 8). We do however feel that the study is cross-sectional. We only have 'follow-up' data on 33 out of 410 physicians from just one out of eight countries that participated in the original study. Moreover, we did not perform any statistical tests on the longitudinal data. Indeed, the small study has a longitudinal aspect, but since this is only a minor part, we consider the study as of cross-sectional nature. We also commented on this in the discussion section. Because of your comment: "There is no discussion around this nor any attempts made to discuss how those being surveyed for a second time, may have influenced or biased the results the second time." we decided to show the results in appendix 2 separately for those participating in the original GUIDANCE study, and for the "new" participants. Please note that we updated appendix 2; 7 physicians returned the survey after we had submitted the manuscript (their data are now included in appendix 2).
Q. There is also no ethical approval mentioned to repeat this survey nor is there justification given for using only one country.
A. We added the following information to the acknowledgement section: "Ethical approval for the substudy was not required since the study did not fulfil the criteria for medical human scientific research under Dutch legislation." (page 25). We justify why we only repeated the survey in the new "Substudy" section, added to the revised manuscript: "Since our aim was only to get a feeling about any time trend, we only repeated the survey in Dutch physicians. Moreover, we did not have the financial and logistic resources to repeat the study in all eight countries." (Methods section, page 8).
Q. In any research, the reliability and validity of the tools determines the rigour of the findings. In this cross-sectional survey, the reliability and validity of the questionnaire utilised is not reported. The lack of validity of the questionnaire is acknowledged within the limitations but this should have been addressed in the methodology of the study.
A. We added additional information to the last paragraph of data collection: "These questions were specifically designed for the purposes of the GUIDANCE study and were not part of a validated questionnaire." (Methods section, page 8).
Q. It is good to see that missing data was acknowledged and this was addressed through statistical analysis.
A. We thank the reviewer for his remark.
Results
Q. There is a sweeping statement made about the number of patients seen per week. It is stated that most German physicians saw 300 patients per week and others saw approximately 100 patients per week. From Table 1 , German physicians saw 275 (SD 150) and Swedish physicians 50 (SD22) per week. When such accurate figures are presented in the Table, it seems unusual for these to be rounded up for the text in the way in which they have been.
A. Thank you for pointing this out. We accidentally stated the mean in the text, and the median in the table. We now also report the median in the text (Results section, page 9). We added "most" since indeed in Sweden physicians saw less than 100 participants per week.
Q. Some of the percentages cited in the rest of this first paragraph of results appear to contradict what is presented in Table 1. A. We double checked Table 1 and edited the numbers cited in the text.
Q. No comment is made on the low reporting of physician's reporting HBA1c according to guidelines.
A. We now comment on this in the first paragraph of the results section: "The target HbA1c in guideline according to the physician varied from 48.5 mmol/mol (6.6%; Germany) to 52.2 mmol/mol (6.9%; the Netherlands)." (Results section, page 10).
Q. Figure 1 is missing from the submitted article.
A. Figure 1 was included as a separate file and can therefore be found at the end of the manuscript. Table 3 could be presented more clearly.
Q. The information presented in the text regarding
A. We added information to describe the results more clearly (Results section, page 15).
Q. The results of the sensitivity analysis should be given and not just cited without any evidence.
A. We have provided the results of the sensitivity analysis in a supplementary table (Appendix 3), which is included in the revised version of the manuscript.
Q. Tables 3 and 4 present data on patient education but no comment is made about this in the results section.
A. In both vignettes there was no statistically significant association for the variable "education by physician" in any of the three linear regressions. Therefore we did not report on this variable. We now added the following to the results section: "There were no associations between the HbA1c level at which insulin will be initiated and all other variables, for example physician's age, practice setting, the target HbA1c in the guideline according to the physician, education by the physician or the presence of a nurse or diabetes educator." (Results section, page 15).
Discussion
Summary of findings Q. It is stated that physicians initiate insulin when HbA1c levels are above 53 mmol/mol for both vignettes however this is not obvious from the data presented.
A. Could it be possible that it does not seem obvious because you could not find Figure 1 ? Figure 1 and Table 2 report about this.
Q. There is no discussion on patient education. All data collected for a study should be discussed and analysed and this appears to be an omission.
A. We choose not to reflect on every single non-significant factor from our linear regression models, since this could easily influence the paper's readability.
Q. The old data set is acknowledged although it was collected as party of a larger study. The authors attempt to address this by altering the design of the study that is inappropriate.
A. We did not try to alter the study design. Since the most recent guidelines all advocate individualised treatment targets, we wanted to get an idea on whether this might have influenced the results. Hence, we performed a small new cross-sectional study.
Q. Under 'Comparison with existing literature' the authors state that the data suggests that the HbA1c is often above 60 mmol/mol before insulin is initiated. Again, this is not obvious from the results.
A. Figure 1 and Table 2 report about this, it might not have been obvious for you since you were unable to see Figure 1 .
Q. The paper would benefit from the more consistent use of terminology e.g. Vignette or case study; Dutch or people from the Netherlands.
A. Thank you for your comment. We replaced 'vignette case' and 'case' with 'vignette' throughout the test. We replaced 'physicians from the Netherlands' by 'Dutch physicians'. Q. Reference 32 is incomplete.
A. We have edited this reference.
Q. Appendices 1 and 2 are irrelevant. Appendix 1: The complete data and percentages needs to be clarified. As it stands, it does not make sense and the mathematics does not add up. It is almost a duplication of Table 1. A. Indeed, Appendix 1 is almost a duplication of Table 1 . We have created this appendix to get an idea on how the missing data were distributed. This appendix suggests that data were not 'missing completely at random', but were 'missing at random'. This means that the missingness depends on the observed data. In our case for example, the percentage of Belgian physicians was higher in the 'missing data group' compared with the 'complete data group'. Also, the percentage of primary care physicians was higher in the 'missing data group'. This information is essential because it dictates which imputation method may be used. Therefore, we did not remove Appendix 1. We understand your comment on 'mathematics does not add up', and therefore have displayed the factor country in one row instead of multiple rows. Q. Appendix 2 refers to the 'add on' study.
A. We do not think Appendix 2 is irrelevant. As mentioned before, the most recent guidelines all propose individualised treatment targets with regard to the HbA1c. We wanted to get an idea on whether this might have influenced the physicians' behaviour. Therefore, we repeated the GUIDANCE survey among Dutch physicians. The results presented in Appendix 2 suggest that physicians would initiate insulin at approximately the same HbA1c levels as in 2009.
VERSION 2 -REVIEW

REVIEWER
Dr Joan McDowell University of Glasgow, Scotland REVIEW RETURNED 30-Jan-2019
GENERAL COMMENTS
The authors have attempted to address some of the issues raised from the first submission. However, there were key aspects that are fundamental flaws in the study design that cannot be addressed by semantics alone. In any research, the reliability and validity of the tools determines the rigour of the findings. In this cross-sectional survey, the reliability and validity of the questionnaire utilised is not reported which is a fundamental flaw. The lack of validity of the questionnaire is acknowledged within the limitations but this should have been addressed in the methodology of the study.
Reference is made to the Sub-Study. There is no mention of ethical approval for repeating this part of the study. There is no justification given for using only one country to repeat the questionnaire.
Results
There is a sweeping statement made about the number of patients seen per week. It is stated that most physicians saw approximately 100 patients per week and yet Swedish physicians saw 50 (SD22) per week. There is no way that 50 is approximately 100. It is not clear where the 6.6% attributed to Germany and 6.9% attributed to the Netherlands relating to target HbA1c in guideline according to physician was derived. Figure 1 is missing from the re-submitted article as it was in the original submission. Page 9 refers to 3 models of analysis. Page 15 mentions a 4th model that has not been previously mentioned and is not referred to in Table 4 Tables 3 and 4 present data on patient education but no comment is made about this in the results section. There is no discussion around the substudy nor any attempts made to discuss how those being surveyed for a second time, may have influenced or biased the results the second time.
Discussion
There is very little discussion on the findings. There is no discussion on patient education. All data collected for a study should be discussed and analysed and this appears to be an omission.
VERSION 2 -AUTHOR RESPONSE
Reviewer 3 provided many comments, which we tried to address in our rebuttal and in the revised version. However, not before but after our rebuttal she now thinks there are fundamental flaws in the study design and she has several additional comments. In some aspects we respectfully disagree with her. Moreover, some of her comments are simply not true, namely the following:
-"The lack of validity of the questionnaire is acknowledged within the limitations but this should have been addressed in the methodology of the study." o
In the methodology section of our manuscript, we wrote the following: "These questions were specifically designed for the purposes of the GUIDANCE study and were not part of a validated questionnaire." (data collection, page 8). Besides, we stated in the discussion section that the kind of the questionnaire could be considered a limitation. We feel that this statement belongs to the discussion section rather than the methods section.
-"There is no mention of ethical approval for repeating this part of the study." o In the ethics approval paragraph we explicitly stated the following: "Ethical approval for the substudy was not required since the study did not fulfil the criteria for medical human scientific research under Dutch legislation." (page 25) -"There is no justification given for using only one country to repeat the questionnaire." o In the methods section, we justified this: "Since our aim was only to get a feeling about any time trend, we only repeated the survey in Dutch physicians. Moreover, we did not have the financial and logistic resources to repeat the study in all eight countries." (sub-study, page 8) -"There is a sweeping statement made about the number of patients seen per week. It is stated that most physicians saw approximately 100 patients per week and yet Swedish physicians saw 50 (SD22) per week. There is no way that 50 is approximately 100." o
In the results section, we wrote the following: "In Germany, physicians saw a median number of 275 patients per week, in contrast to physicians from most other countries who saw approximately 100 patients per week.". We aimed to make a general comment by writing "physicians from MOST other countries saw …", unfortunately Dr Joan McDowell misinterpreted this as "most physicians saw …".
-" Figure 1 is missing from the re-submitted article as it was in the original submission." o In both submissions we have included Figure 1 as a separate file, and therefore it can be found at the end of the manuscript. We have double-checked the print proofs and Figure 1 is present.
Dr Joan McDowell has repeated her comments on reporting and discussing the non-statistically significant findings on patient education. We fully agree with her on the importance of diabetes patient education. However, for the purpose of readability and clarity of our manuscript, we decided not to delve deeper in this non-significant factor. If we would have done that, we could have been blamed for emphasising non-significant findings.
Nevertheless, some of her comments are useful: -"Page 9 refers to 3 models of analysis. Page 15 mentions a 4th model that has not been previously mentioned and is not referred to in Table 4"   o We mistakenly made a typo, model 4 should be model 3 -"It is not clear where the 6.6% attributed to Germany and 6.9% attributed to the Netherlands relating to target HbA1c in guideline according to physician was derived." o This is the HbA1c in % instead of mmol/mol units, but indeed is confusing
To summarise: most of Dr McDowell's comments in this second stage of review are not justified, based on the text of the revised manuscript. We respectfully disagree with the reviewer's statement that the abovementioned issues are "key aspects that are fundamental flaws in the study design". The comments that are useful are minor comments and we would be more than happy to revise our manuscript once more.
